218 filings
Page 3 of 11
8-K
aq8s2 2e7relg4
10 Nov 22
Optinose Reports Third Quarter 2022 Financial Results
7:01am
8-K/A
c4xwv9 9q
27 Sep 22
Departure of Directors or Certain Officers
4:38pm
8-K
lg2b jkkf
23 Sep 22
Entry into a Material Definitive Agreement
8:09am
8-K
tjm0ha14b
11 Aug 22
Optinose Reports Second Quarter 2022 Financial Results
7:10am
8-K
ib6hl8f
13 Jul 22
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program
7:00am
8-K
cibjt8i4pr wa
8 Jul 22
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
7:00am
8-K
x62ygb16l3ne fnlux
1 Jul 22
Termination of a Material Definitive Agreement
4:34pm
8-K
zecb5uif
13 Jun 22
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
7:01am
8-K
nhprx7nsu 1unzqbj
9 Jun 22
Submission of Matters to a Vote of Security Holders
12:47pm
8-K
ov4vs
3 Jun 22
Optinose Announces Departure of Chief Financial Officer
7:00am
8-K
vzvb9 d8z17o12
12 May 22
Optinose Reports First Quarter 2022 Financial Results
7:00am
DEFA14A
0wuy6ktkemi9jmt 6gqd
26 Apr 22
Additional proxy soliciting materials
4:07pm
8-K
vh2lxzrvilfc5yk
26 Apr 22
Optinose Announces Appointment of R. John Fletcher to the Board
8:17am
8-K
ed1cceaas4nm0q3833
14 Mar 22
Other Events
4:48pm
S-8
5b2rdtcucd
8 Mar 22
Registration of securities for employees
11:12am